FR3100819B1 - Production et fonctionnalisation de nanoparticules dérivées du phage T5 et utilisations thérapeutiques - Google Patents

Production et fonctionnalisation de nanoparticules dérivées du phage T5 et utilisations thérapeutiques Download PDF

Info

Publication number
FR3100819B1
FR3100819B1 FR1910305A FR1910305A FR3100819B1 FR 3100819 B1 FR3100819 B1 FR 3100819B1 FR 1910305 A FR1910305 A FR 1910305A FR 1910305 A FR1910305 A FR 1910305A FR 3100819 B1 FR3100819 B1 FR 3100819B1
Authority
FR
France
Prior art keywords
phage
functional fragment
fragment
relates
capsid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1910305A
Other languages
English (en)
Other versions
FR3100819A1 (fr
Inventor
Pascale Boulanger
Emeline Vernhes
Nicolas Ducrot
Cherif Linda Larbi
Karim Benihoud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Paris Saclay
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Paris Sud Paris 11
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1910305A priority Critical patent/FR3100819B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Paris Sud Paris 11 filed Critical Centre National de la Recherche Scientifique CNRS
Priority to US17/761,403 priority patent/US20230190925A1/en
Priority to CA3154856A priority patent/CA3154856A1/fr
Priority to JP2022518200A priority patent/JP2022549257A/ja
Priority to EP20785815.0A priority patent/EP4031668A1/fr
Priority to PCT/FR2020/051628 priority patent/WO2021053309A1/fr
Priority to CN202080079575.0A priority patent/CN114729375A/zh
Publication of FR3100819A1 publication Critical patent/FR3100819A1/fr
Application granted granted Critical
Publication of FR3100819B1 publication Critical patent/FR3100819B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des capsides de phage T5 dépourvue d’ADN génomique dudit phage et exposant, à sa surface, au moins une protéine de fusion d’intérêt. L’invention concerne en particulier une capside de phage T5 dépourvue d’ADN génomique dudit phage et exposant, à sa surface, au moins une protéine de fusion, ladite protéine de fusion comprenant : - au moins un fragment de peptide ou de protéine ayant au moins 80% d’identité avec un fragment d’une protéine de décoration pb10 ; et - au moins un fragment fonctionnel d’un antigène, ou au moins un fragment fonctionnel d’une toxine, ou au moins un fragment de récepteur, ou au moins un fragment fonctionnel d’un signal d’adressage ou de ciblage ou de transport, ou au moins un fragment fonctionnel d’une enzyme, ou au moins un fragment fonctionnel d’une hormone, ou au moins un fragment fonctionnel d’un anticorps, ou au moins un antigène, ou au moins une toxine, ou au moins un récepteur, ou au moins un signal d’adressage ou de ciblage ou de transport, ou au moins une enzyme, ou au moins une hormone, ou au moins un anticorps, ou une combinaison quelconque de ceux-ci. La présente invention porte également sur les méthodes de production d’une telle capside et sur des vecteurs permettant leur production. L’invention concerne en outre les protéines de fusion d’intérêt exposées sur la capside et les acides nucléiques les codant. L’invention concerne également des nanoparticules comprenant ces capsides fonctionnalisées, des compositions pharmaceutiques comprenant ces nanoparticules et/ou ces capsides fonctionnalisées, ainsi que leurs utilisations thérapeutiques, notamment comme médicament et/ou comme vaccin.
FR1910305A 2019-09-18 2019-09-18 Production et fonctionnalisation de nanoparticules dérivées du phage T5 et utilisations thérapeutiques Active FR3100819B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR1910305A FR3100819B1 (fr) 2019-09-18 2019-09-18 Production et fonctionnalisation de nanoparticules dérivées du phage T5 et utilisations thérapeutiques
CA3154856A CA3154856A1 (fr) 2019-09-18 2020-09-18 Production et fonctionnalisation de nanoparticules derivees du phage t5 et utilisations therapeutiques
JP2022518200A JP2022549257A (ja) 2019-09-18 2020-09-18 ファージｔ５由来ナノ粒子の作製及び機能化並びに治療用途
EP20785815.0A EP4031668A1 (fr) 2019-09-18 2020-09-18 Production et fonctionnalisation de nanoparticules dérivées du phage t5 et utilisations thérapeutiques
US17/761,403 US20230190925A1 (en) 2019-09-18 2020-09-18 Production and functionalization of nanoparticles derived from phage t5 and therapeutic uses
PCT/FR2020/051628 WO2021053309A1 (fr) 2019-09-18 2020-09-18 Production et fonctionnalisation de nanoparticules dérivées du phage t5 et utilisations thérapeutiques
CN202080079575.0A CN114729375A (zh) 2019-09-18 2020-09-18 源自噬菌体t5的纳米颗粒的生产和功能化以及治疗用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1910305 2019-09-18
FR1910305A FR3100819B1 (fr) 2019-09-18 2019-09-18 Production et fonctionnalisation de nanoparticules dérivées du phage T5 et utilisations thérapeutiques

Publications (2)

Publication Number Publication Date
FR3100819A1 FR3100819A1 (fr) 2021-03-19
FR3100819B1 true FR3100819B1 (fr) 2024-04-19

Family

ID=71094391

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1910305A Active FR3100819B1 (fr) 2019-09-18 2019-09-18 Production et fonctionnalisation de nanoparticules dérivées du phage T5 et utilisations thérapeutiques

Country Status (7)

Country Link
US (1) US20230190925A1 (fr)
EP (1) EP4031668A1 (fr)
JP (1) JP2022549257A (fr)
CN (1) CN114729375A (fr)
CA (1) CA3154856A1 (fr)
FR (1) FR3100819B1 (fr)
WO (1) WO2021053309A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE359295T1 (de) * 2002-06-11 2007-05-15 Glaxosmithkline Biolog Sa Immunogene zusammensetzungen

Also Published As

Publication number Publication date
WO2021053309A1 (fr) 2021-03-25
CA3154856A1 (fr) 2021-03-25
JP2022549257A (ja) 2022-11-24
CN114729375A (zh) 2022-07-08
EP4031668A1 (fr) 2022-07-27
FR3100819A1 (fr) 2021-03-19
US20230190925A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
Subramanian et al. Emerging concepts in the pathogenesis of the Streptococcus pneumoniae: from nasopharyngeal colonizer to intracellular pathogen
Unciti-Broceta et al. Specific cell targeting therapy bypasses drug resistance mechanisms in African trypanosomiasis
Kim Pathogenesis of bacterial meningitis: from bacteraemia to neuronal injury
JP5959589B2 (ja) 免疫調節組成物およびその使用方法
Liu et al. D‐peptides as recognition molecules and therapeutic agents
Blasi et al. Understanding the burden of pneumococcal disease in adults
Town et al. Characterization of murine immunoglobulin G antibodies against human amyloid-β1–42
Muthumani et al. Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody
MA56289B1 (fr) Mutéines d'interleukine-21 et méthodes de traitement
Tykvart et al. Comparative analysis of monoclonal antibodies against prostate‐specific membrane antigen (PSMA)
FI3408295T3 (fi) Bispesifisiä vasta-ainekonstrukteja käsittävä farmaseuttinen koostumus
Lingasamy et al. Tumor-penetrating peptide for systemic targeting of Tenascin-C
Dénes et al. Streptococcus pneumoniae worsens cerebral ischemia via interleukin 1 and platelet glycoprotein Ibα
Iovino et al. Platelet endothelial cell adhesion molecule-1, a putative receptor for the adhesion of Streptococcus pneumoniae to the vascular endothelium of the blood-brain barrier
JP2014533242A (ja) ＩｇＧによる細胞内中和に関する方法および組成物
CN101815724A (zh) 用于将轭合至其的试剂递送至组织的抑肽酶样多肽
Hurst et al. Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin®)
MA38194B1 (fr) Anticorps anti-ceacam5 et leurs utilisations
Hu et al. A novel and efficient nicotine vaccine using nano-lipoplex as a delivery vehicle
MA29459B1 (fr) Vaccins
Lattar et al. Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis
Whelan et al. Modulating the blood–brain barrier: a comprehensive review
Bachran et al. Cytolethal distending toxin B as a cell-killing component of tumor-targeted anthrax toxin fusion proteins
Ponzoni et al. Enhancement of tumor homing by chemotherapy‐loaded nanoparticles
Sano et al. Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20210319

PLFP Fee payment

Year of fee payment: 3

TQ Partial transmission of property

Owner name: UNIVERSITE PARIS-SACLAY, FR

Effective date: 20211221

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (, FR

Effective date: 20211221

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5